A Multi-center Long Term Efficacy Trial of the GFX For Reduction of Glabellar Furrowing
This study has been completed.
Sponsor:
Advanced Cosmetic Intervention
Information provided by (Responsible Party):
Advanced Cosmetic Intervention
ClinicalTrials.gov Identifier:
NCT00611273
First received: January 28, 2008
Last updated: January 22, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Long term efficacy study of GFX for patients undergoing reduction of glabellar furrowing
| Condition | Intervention | Phase |
|---|---|---|
|
Glabellar Furrowing |
Device: GFX |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Multi-center Long Term Efficacy Trial of the GFX For Reduction of Glabellar Furrowing |
Further study details as provided by Advanced Cosmetic Intervention:
Primary Outcome Measures:
- Time at which the patient no longer shows an improvement from the base line RNKLS score indicating that the initially successful GFX procedure is no longer effective at a scheduled follow-up visit. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Minimal or transient incidence of minor unanticipated adverse events. [ Time Frame: 30 days ] [ Designated as safety issue: No ]
| Enrollment: | 260 |
| Study Start Date: | September 2007 |
| Study Completion Date: | April 2008 |
| Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Patients who have presented to the investigator for correction of glabellar furrows, as classified per the Rated Numeric Kinetic Line Scale Score for Facial Wrinkles Secondary to Hyperkinetic Function (Note: Class 1 or Higher)7 (Appendix R) are candidates for this study.
|
Device: GFX
The GFX system employs minimally invasive technique utilizing Bi-polar (radio frequency) RF technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
Other Name: RF Nerve Ablation Device
|
Detailed Description:
A Multi-center Long Term Efficacy Trial of GFX for the Reduction of Glabellar Furrowing
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria: The patient will be included if:
- Has no medical contraindication
- Presents for correction of glabellar furrows, as classified per the Rated Numeric Kinetic Line Scale Score for Facial Wrinkles Secondary to Hyperkinetic Function (Class 1 or Higher)
- Is at least 18 years of age
- Signs a written informed consent
- Understands and accepts the obligation to present for scheduled follow-up visits
- Understands that the GFX procedure may not be successful
- Presents at the one month follow-up visit with an improvement from the base line RNKLS score
Exclusion Criteria: The patient will be excluded if:
- Has had an injection of botulinum toxin to the target area within the previous 4 months and still exhibits a positive cosmetic effect to the glabellar frown.
- Has had silicone, fat, collagen or a synthetic material placed in the glabellar region or surgical correction or excision of the glabellar furrows
- Has a known bleeding disorder
- Pregnant
- Has received or is anticipated to receive anti-platelets, anti-coagulants, thrombolytics, or cancer therapy
- Is receiving systemic corticosteroids or anabolic steroids (standard doses of inhaled or nasal corticosteroids are acceptable)
- Has a history of chronic or recurrent infection or compromised immune system
- Has severe allergies manifested by a history of anaphylaxis
- Has known lidocaine hypersensitivity
- Is enrolled in another study
- Has history of keloid formation
- The investigator believes the patient is not a suitable candidate for the GFX procedure, or is not likely to receive cosmetic benefitPresents at the one month follow-up visit with no improvement from the base line RNKLS score
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00611273
Locations
| United States, California | |
| Paul S. Nassif, MD, FACS | |
| Beverly Hills, California, United States, 90212 | |
| James Newman | |
| San Mateo, California, United States, 94401 | |
| United States, Florida | |
| Michael E. Jansin, MD | |
| Tampa, Florida, United States, 33613 | |
| United States, Georgia | |
| Foad Nahai, M.D., F.A.C.S. | |
| Atlanta, Georgia, United States, 30327 | |
| United States, Illinois | |
| Steven P. Block, MD | |
| Highland Park, Illinois, United States, 60035 | |
| United States, Missouri | |
| Keith LaFerriere, MD | |
| Springfield, Missouri, United States, 65807 | |
| United States, South Carolina | |
| J. Smythe Rich, III, M.D | |
| Columbia, South Carolina, United States, 29203 | |
| United States, Texas | |
| Russell W. Kridel, MD | |
| Houston, Texas, United States, 77030 | |
| United States, Wisconsin | |
| Roger C. Mixter, MD | |
| Milwaukee, Wisconsin, United States, 53217 | |
| Canada, Ontario | |
| David A. Ellis, MD | |
| Toronto, Ontario, Canada, M2N 1M9 | |
Sponsors and Collaborators
Advanced Cosmetic Intervention
Investigators
| Study Director: | James Newman, MD | Premier Plastic Surgery |
More Information
No publications provided
| Responsible Party: | Advanced Cosmetic Intervention |
| ClinicalTrials.gov Identifier: | NCT00611273 History of Changes |
| Other Study ID Numbers: | ACI 007-02, WIRB 20062119 |
| Study First Received: | January 28, 2008 |
| Last Updated: | January 22, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Advanced Cosmetic Intervention:
|
Glabellar Furrowing |
ClinicalTrials.gov processed this record on June 18, 2013